No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 2, 2002, Pages 137-146

  Walter, Hauke ^a   Löw, Peter ^a   Harrer, Thomas ^a   Schmitt, Matthias ^a   Schwingel, Eva ^a   Tschochner, Monika ^a   Helm, Martin ^b   Korn, Klaus ^a   Überla, Klaus ^c   Schmidt, Barbara ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Praxis Dr G Abelein/Dr M Helm   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Drug resistance; HIV; Persistence; Treatment interruption; Viral reservoir

Indexed keywords

ABACAVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0036797122     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200210010-00003     Document Type: Article

References (40)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Vandamme AM, Van Vaerenbergh K, De Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivit-Chem Chemother 1998;9:187-203.
4. Montaner J, Mellors J. Progress in HIV-1 therapy continues on upward track. Lancet 1999;353:565.
5. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunologic changes after stopping effective antiretroviral therapy. AIDS 1999:13:F79-86.
6. Verhofstede C, Wanzeele FV, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-6.
7. Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000;14:2247-55.
8. Miller V. Sabin C, Hertogs K, et al. Virological and immunologic effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-67.
9. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997;71:1089-96.
10. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitortreated patients. J Virol 1998;72:7632-7.
11. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998;72:3773-8.
12. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80.
13. Benson CA. Structured treatment interruption in HIV infection. AIDS Read 2001;11:99-102.
14. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001;75:6410-7.
15. Delaugerre C, Valantin MA, Mouroux M, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001;15:2189-91.
16. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998;280:1871-3.
17. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996;70:3763-9.
18. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997;71:6662-70.
19. Zennou V, Mammano F, Paulous S, et al. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998;72:3300-6.
20. Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996;174:204-9.
21. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-5.
22. Romanelli F, Pomeroy C, Smith KM. Hydroxyurea to inhibit human immunodeficiency virus-I replication. Pharmacotherapy 1999;19:196-204.
23. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Überla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 1999;13:71-80.
24. Means RE, Greenough T, Desrosiers RC. Neutralization sensitivity of cell culture-passaged simian immonodeficiency virus. J Virol 1997;71:7895-902.
25. Schinazi RF, Larder B, Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update, Int Antivir News 2000;8:65-92.
26. Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000;44;568-73.
27. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999;13:2349-59.
28. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;76:1753-61.
29. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001;26(Suppl 1):S25-33.
30. Garcia-Lerma JG, Nidtha S, Blumoff K, et al. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 2001;98:13907-12.
31. Bleiber G, Munoz M, Ciuffi A, et al. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 2001;75:3291-300.
32. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193-7.
33. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
34. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
35. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.
36. Lambotte O, Taoufik Y, de Goer MG, et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:114-9.
37. Igarashi T, Brown CR, Endo Y, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A 2001;98:658-63.
38. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999;17:625-56.
39. Hlavacek WS, Stilianakis NI, Notermans DW, et al. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci U S A 2000;97:10966-71.
40. Smith BA, Gartner S, Liu Y, et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol 2001;166:690-6.